Review our commercial product billing guide

Dec. 2023Important Notices
Pennsylvania Act 1 of 2023, signed into law this May, requires insurance policies to cover all costs associated with one supplemental breast screening every year for women with increased risk of breast cancer via MRI or ultrasound.

To assist providers in navigating this new law, we are offering recommendations as a guide to aid with compliance.

We encourage you to review our commercial product billing guide for recommendations around complying with Pennsylvania Act 1 of 2023.

If you have any questions or concerns, please contact your physician account executive or call Provider Services at 1-866-918-1595.

Recent Announcements

Voluntary nationwide recall: Cetirizine (Unique – July)

Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) is recalling four lots (GY825029, GY825030, GY825031, GY825032) of Cetirizine Hydrochloride Tablets USP 5 mg. Cetirizine is used for the relief of allergy symptoms, including itchy, red, watery eyes and itchy skin.
Jul. 2026Pharmacy Updates

August 2026 UPMC for You and UPMC Community HealthChoices Formulary Updates

Effective Aug. 15, 2026, UPMC for You and UPMC Community HealthChoices are updating their formularies.
Jul. 2026Pharmacy Updates

Give feedback on your experience with UPMC Health Plan

 You may be invited to participate in a 2026 Press Ganey provider satisfaction survey, which will begin next month. This survey will be given to a random sampling of in-network primary care providers.
Jul. 2026Important Notices